Finance

Lists
PRCT:NASDAQ
Procept Biorobotics Corp
$20.07
0.00%
(0.00) 1D
Sep 10, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PRCT...
Mkt. cap
1.15B
Avg. vol.
1.43M
Volume
77.00
52-wk high
$40.10
52-wk low
$16.66
EPS
-$1.95
Beta
0.91
Shares outstanding
57.27M
No. of employees
888
Mkt. cap
1.15B
Avg. vol.
1.43M
Volume
77.00
52-wk high
$40.10
52-wk low
$16.66
EPS
-$1.95
Beta
0.91
Shares outstanding
57.27M
No. of employees
888
News stories
From web sources and news partners
About Procept Biorobotics Corp
CEO-
Employees888
Founded2007
HeadquartersSan Jose, California, United States
SectorMedical device
Websiteprocept-biorobotics.com
Analyst ratings
Based on 11 analysts giving stock ratings to PRCT in the past 3 months
Hold
Buy
3
Hold
7
Sell
1
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for PRCT in the last 3 months.
Highest
Current $20.07
$29.00 (+44.49%)
Average
$23.13 (+15.25%)
Lowest
$19.00 (-5.33%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ryan Zimmerman
BTIG
Hold
Maintained
-
-
08/31/2026
Brandon Vazquez
William Blair
Hold
Downgraded
-
-
08/08/2026
Stephanie Piazzola
Bank of America Securities
Sell
Maintained
-
-
08/05/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$23.00
+14.6%
08/05/2026
Richard Newitter
Truist Financial
Hold
Reiterated
$21.00
+4.6%
08/05/2026
Patrick Wood
UBS
Hold
Reiterated
$20.00
-0.3%
08/05/2026
Matthew O'Brien
Piper Sandler
Buy
Maintained
$25.00
+24.6%
08/05/2026
David Rescott
Robert W. Baird
Hold
Maintained
$20.00
-0.3%
08/05/2026
Nathan Treybeck
Wells Fargo
Hold
Downgraded
$19.00
-5.3%
08/05/2026
Josh Jennings
TD Cowen
Buy
Reiterated
$28.00
+39.5%
08/05/2026
Danielle Antalffy
UBS
Hold
Downgraded
$20.00
-0.3%
07/28/2026
Mike Kratky
Leerink Partners
Hold
Downgraded
$29.00
+44.5%
06/12/2026
Suraj Kalia
Oppenheimer
Hold
Downgraded
$60.00
+199%
02/26/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
83.33M
76.38M
83.13M
94.50M
Cost of goods sold
29.32M
30.07M
29.18M
35.02M
Cost of revenue
29.32M
30.07M
29.18M
35.02M
Research and development expenses
18.19M
19.06M
21.46M
20.10M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
59.01M
58.30M
65.09M
69.67M
Operating expense
77.20M
77.35M
86.55M
89.77M
Total operating expenses
106.52M
107.42M
115.74M
124.79M
Operating income
-23.19M
-31.04M
-32.61M
-30.29M
Other non operating income
-
-156.00K
-
-
EBT including unusual items
-21.41M
-29.66M
-31.68M
-26.77M
EBT excluding unusual items
-21.41M
-29.66M
-31.68M
-29.67M
Income tax expense
-
190.00K
-43.00K
94.00K
Effective tax rate
-
-0.64%
0.14%
-0.35%
Other operating expenses
-
-
-
-
Net income
-21.41M
-29.84M
-31.64M
-26.86M
Net profit margin
-25.70%
-39.07%
-38.06%
-28.42%
Earnings per share
-0.38
-0.53
-0.56
-0.47
Interest and investment income
2.70M
2.44M
1.74M
1.46M
Interest expense
-919.00K
-894.00K
-818.00K
-842.00K
Net interest expenses
1.78M
1.54M
925.00K
623.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-21.57M
-29.33M
-30.87M
-28.30M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps